Cargando…

Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer

BACKGROUND: Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer. One of the side effects of bevacizumab is gastrointestinal perforation. This study was desig...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seijong, Shin, Jung Kyong, Park, Yoonah, Huh, Jung Wook, Kim, Hee Cheol, Yun, Seong Hyeon, Lee, Woo Yong, Cho, Yong Beom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639472/
https://www.ncbi.nlm.nih.gov/pubmed/36353568
http://dx.doi.org/10.3389/fonc.2022.1018458
_version_ 1784825648917774336
author Kim, Seijong
Shin, Jung Kyong
Park, Yoonah
Huh, Jung Wook
Kim, Hee Cheol
Yun, Seong Hyeon
Lee, Woo Yong
Cho, Yong Beom
author_facet Kim, Seijong
Shin, Jung Kyong
Park, Yoonah
Huh, Jung Wook
Kim, Hee Cheol
Yun, Seong Hyeon
Lee, Woo Yong
Cho, Yong Beom
author_sort Kim, Seijong
collection PubMed
description BACKGROUND: Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer. One of the side effects of bevacizumab is gastrointestinal perforation. This study was designed to identify the effect of bevacizumab in intestinal anastomosis site healing. METHODS: From January 2010 to December 2020, patients diagnosed with stage IV colorectal cancer treated with palliative chemotherapy or chemoradiotherapy followed by radical surgery were retrospectively reviewed. Clinical signs or symptoms and computed tomography were tools used for diagnosing anastomosis site leakage. The patients were divided into two groups, the bevacizumab group (n = 136) and the non-bevacizumab group (n = 124). RESULTS: Among the 260 patients 14 (5.4%) patients were diagnosed with anastomosis site leakage. In the bevacizumab group, 13 (9.6%) patients were diagnosed with anastomotic leakage. In the non-bevacizumab group, 1 (0.8%) patient was diagnosed with anastomotic leakage. Anastomosis site leakage was significantly higher in the bevacizumab treatment group (P < 0.001). In the bevacizumab group, period of drug discontinuation before surgery was factor associated with anastomosis site leakage in multivariable analysis (P = 0.031). CONCLUSION: Stage IV colorectal patients treated with bevacizumab before radical surgery for primary cancer should be carefully observed of anastomosis site leakage after surgery, and the period of drug discontinuation before surgery should be longer than 5 weeks to avoid anastomosis site leakage.
format Online
Article
Text
id pubmed-9639472
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96394722022-11-08 Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer Kim, Seijong Shin, Jung Kyong Park, Yoonah Huh, Jung Wook Kim, Hee Cheol Yun, Seong Hyeon Lee, Woo Yong Cho, Yong Beom Front Oncol Oncology BACKGROUND: Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor and is used in combination with first-line chemotherapy in the treatment of metastatic colorectal cancer. One of the side effects of bevacizumab is gastrointestinal perforation. This study was designed to identify the effect of bevacizumab in intestinal anastomosis site healing. METHODS: From January 2010 to December 2020, patients diagnosed with stage IV colorectal cancer treated with palliative chemotherapy or chemoradiotherapy followed by radical surgery were retrospectively reviewed. Clinical signs or symptoms and computed tomography were tools used for diagnosing anastomosis site leakage. The patients were divided into two groups, the bevacizumab group (n = 136) and the non-bevacizumab group (n = 124). RESULTS: Among the 260 patients 14 (5.4%) patients were diagnosed with anastomosis site leakage. In the bevacizumab group, 13 (9.6%) patients were diagnosed with anastomotic leakage. In the non-bevacizumab group, 1 (0.8%) patient was diagnosed with anastomotic leakage. Anastomosis site leakage was significantly higher in the bevacizumab treatment group (P < 0.001). In the bevacizumab group, period of drug discontinuation before surgery was factor associated with anastomosis site leakage in multivariable analysis (P = 0.031). CONCLUSION: Stage IV colorectal patients treated with bevacizumab before radical surgery for primary cancer should be carefully observed of anastomosis site leakage after surgery, and the period of drug discontinuation before surgery should be longer than 5 weeks to avoid anastomosis site leakage. Frontiers Media S.A. 2022-10-21 /pmc/articles/PMC9639472/ /pubmed/36353568 http://dx.doi.org/10.3389/fonc.2022.1018458 Text en Copyright © 2022 Kim, Shin, Park, Huh, Kim, Yun, Lee and Cho https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kim, Seijong
Shin, Jung Kyong
Park, Yoonah
Huh, Jung Wook
Kim, Hee Cheol
Yun, Seong Hyeon
Lee, Woo Yong
Cho, Yong Beom
Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
title Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
title_full Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
title_fullStr Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
title_full_unstemmed Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
title_short Bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
title_sort bevacizumab increases the risk of anastomosis site leakage in metastatic colorectal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639472/
https://www.ncbi.nlm.nih.gov/pubmed/36353568
http://dx.doi.org/10.3389/fonc.2022.1018458
work_keys_str_mv AT kimseijong bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer
AT shinjungkyong bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer
AT parkyoonah bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer
AT huhjungwook bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer
AT kimheecheol bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer
AT yunseonghyeon bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer
AT leewooyong bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer
AT choyongbeom bevacizumabincreasestheriskofanastomosissiteleakageinmetastaticcolorectalcancer